Abstract
AbstractDespite the multifactorial nature of glaucoma, it is evident that treatments to lower the intraocular pressure (IOP) decrease the rate of glaucomatous progression. Within the available treatments, IOP‐lowering eye drops are the far most common strategy. In 2011, the most prescribed anti‐glaucomatous eye drops, Xalatan, went out of patent and since then multiple generic eye drops has entered the market. Although it is an obvious benefit to eradicate the monopoly, the minimum requirements for the introduction of generic eye drops are worrying. Thus, increasing evidence have shown significant differences between generic anti‐glaucomatous eye drops and their brand name products. Moreover, differences in‐between the generic eye drops exist. To complicate it even more, generic Xalatan has changed and is now different from its original form. Overall, it is a jungle and only by improving research, education, and behaviour, the availability of the various treatment options will be rewarding. With a humorous, but serious, angle, the jungle of current available anti‐glaucomatous eye drops will be compared to the challenging career path of women in science.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
